Peimine inhibits variants of SARS‐CoV ‐2 cell entry via blocking the interaction between viral spike protein and ACE2

Author:

Wang Wei‐Jan12,Chen Yeh234,Su Wen‐Chi56,Liu Yen‐Yi7,Shen Wan‐Jou8,Chang Wei‐Chao9,Huang Sheng‐Teng10111213,Lin Cheng‐Wen14,Wang Yu‐Chuan234,Yang Chia‐Shin234,Hou Mei‐Hui234,Chou Yu‐Chi15,Wu Yang‐Chang161718,Wang Shao‐Chun2891920,Hung Mien‐Chie28920ORCID

Affiliation:

1. Department of Biological Science and Technology China Medical University Taichung Taiwan

2. Research Center for Cancer Biology China Medical University Taichung Taiwan

3. Gradaute Institute of New Drug Development China Medical University Taichung Taiwan

4. New Drug Development Center China Medical University Taichung Taiwan

5. International Master's Program of Biomedical Sciences China Medical University Taichung Taiwan

6. Research Center for Emerging Viruses China Medical University Hospital Taichung Taiwan

7. Department of Public Health China Medical University Taichung Taiwan

8. College of Medicine, Graduate Institute of Biomedical Sciences China Medical University Taichung Taiwan

9. Center for Molecular Medicine China Medical University Hospital Taichung Taiwan

10. School of Chinese Medicine China Medical University Taichung Taiwan

11. Department of Chinese Medicine, Research Cancer Center for Traditional Chinese Medicine China Medical University Hospital Taichung Taiwan

12. Department of Medical Research China Medical University Hospital Taichung Taiwan

13. An‐Nan Hospital, China Medical University Tainan Taiwan

14. Department of Medical Laboratory Science and Biotechnology China Medical University Taichung Taiwan

15. RNA Technology Platform and Gene Manipulation Core, Biomedical Translation Research Center (BioTReC) Academia Sinica Taipei Taiwan

16. Chinese Medicine Research and Development Center China Medical University Hospital, China Medical University Taichung Taiwan

17. Graduate Institute of Integrated Medicine, College of Chinese Medicine China Medical University Taichung Taiwan

18. Department of Medical Laboratory Science and Biotechnology, College of Medical and Health Science Asia University Taichung Taiwan

19. Cancer Biology and Drug Discovery Ph.D. Program China Medical University Taichung Taiwan

20. Department of Biotechnology Asia University Taichung Taiwan

Funder

China Medical University

China Medical University Hospital

Ministry of Science and Technology, Taiwan

Publisher

Hindawi Limited

Subject

Cell Biology,Pharmacology,Food Science,Biophysics

Cited by 9 articles. 订阅此论文施引文献 订阅此论文施引文献,注册后可以免费订阅5篇论文的施引文献,订阅后可以查看论文全部施引文献

同舟云学术

1.学者识别学者识别

2.学术分析学术分析

3.人才评估人才评估

"同舟云学术"是以全球学者为主线,采集、加工和组织学术论文而形成的新型学术文献查询和分析系统,可以对全球学者进行文献检索和人才价值评估。用户可以通过关注某些学科领域的顶尖人物而持续追踪该领域的学科进展和研究前沿。经过近期的数据扩容,当前同舟云学术共收录了国内外主流学术期刊6万余种,收集的期刊论文及会议论文总量共计约1.5亿篇,并以每天添加12000余篇中外论文的速度递增。我们也可以为用户提供个性化、定制化的学者数据。欢迎来电咨询!咨询电话:010-8811{复制后删除}0370

www.globalauthorid.com

TOP

Copyright © 2019-2024 北京同舟云网络信息技术有限公司
京公网安备11010802033243号  京ICP备18003416号-3